Your Biologics Partner
List of projects implemented with European funds
Why Mabion?
- Biologics expertise from cell line development to commercial GMP manufacturing
- Flexible partnership model focused on long‑term collaboration and shared success
- Scalable manufacturing capacity designed for clinical and commercial supply needs
- Competitive European cost base combined with highly skilled biotech talent
Our expertise
Co-Development Partnership Models in Biologics Programs
Co-Development Partnership as a Value-Driven Model Co-development indicates a fundamental shift in the collaboration pattern between biopharma and CDMOs. Traditionally, a CDMO (Contract Development and Manufacturing Organization) was a hired contractor: paid a fee to perform discrete tasks, with an eye on minimizing its own costs and risks. Often this meant a narrow focus on […]
ADC Manufacturing – A Comprehensive Guide to Drug Substance Manufacturing Services
What Makes ADC Manufacturing Distinct from Conventional Biologics Production? Manufacturing an antibody-drug conjugate is inherently more complex than manufacturing a typical biologic alone. In conventional biologics production, the process centers on cultivating cells to express the protein and then purifying that single biomolecule. By contrast, ADC manufacturing involves multiple components and steps: the biologic (antibody) must first be produced, the […]
The New Era of Biosimilar Development: Seizing the Opportunity Under EMA’s Streamlined Guidelines
Current bottlenecks in biosimilar development The Biosimilar developers today face significant challenges under the traditional development paradigm. Bringing a biosimilar to market typically takes 7-9 years at a cost often exceeding $100–$200 million. A major contributor is the large Phase III confirmatory trial, which can enroll hundreds of patients and last several years. These comparative […]
Strategies for High-Quality Recombinant Protein Production
Factors Affecting the Quality of Recombinant Protein Production Recombinant protein production is most rigorously defined as the consistent achievement of a clinically justified Critical Quality Attribute (CQA) set through a quality control strategy. In biologics the dominant determinants of this CQA landscape originate bioprocessing. Early choices in upstream and bioreactor production mode establish a area for product quality that downstream purification can only bias, […]
